$6.03
0.67% today
Nasdaq, Aug 26, 05:28 pm CET
ISIN
US92511W1080
Symbol
VRCA

Verrica Pharmaceuticals Inc Stock price

$5.99
-0.62 9.38% 1M
-0.80 11.78% 6M
-1.01 14.43% YTD
-19.71 76.69% 1Y
-34.01 85.03% 3Y
-81.91 93.19% 5Y
-169.01 96.58% 10Y
-169.01 96.58% 20Y
Nasdaq, Closing price Mon, Aug 25 2025
+0.53 9.61%
ISIN
US92511W1080
Symbol
VRCA
Industry

Key metrics

Basic
Market capitalization
$56.6m
Enterprise Value
$79.3m
Net debt
$22.8m
Cash
$15.4m
Shares outstanding
9.3m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
3.8 | 2.1
EV/Sales
5.4 | 2.9
EV/FCF
negative
P/B
negative
Financial Health
Equity Ratio
-18.2%
Return on Equity
776.7%
ROCE
-391.7%
ROIC
-
Debt/Equity
-2.2
Financials (TTM | estimate)
Revenue
$14.7m | $27.6m
EBITDA
$-37.7m | $-31.5m
EBIT
$-38.7m | $-23.6m
Net Income
$-48.6m | $-24.3m
Free Cash Flow
$-47.4m
Growth (TTM | estimate)
Revenue
5.7% | 264.2%
EBITDA
52.8% | 51.2%
EBIT
52.1% | 64.1%
Net Income
44.1% | 68.3%
Free Cash Flow
28.2%
Margin (TTM | estimate)
Gross
86.5%
EBITDA
-256.6% | -114.3%
EBIT
-263.4%
Net
-330.5% | -88.0%
Free Cash Flow
-322.1%
More
EPS
$-5.1
FCF per Share
$-5.1
Short interest
2.9%
Employees
71
Rev per Employee
$110.0k
Show more

Is Verrica Pharmaceuticals Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,019 stocks worldwide.

Verrica Pharmaceuticals Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

11 Analysts have issued a Verrica Pharmaceuticals Inc forecast:

7x Buy
64%
4x Hold
36%

Analyst Opinions

11 Analysts have issued a Verrica Pharmaceuticals Inc forecast:

Buy
64%
Hold
36%

Financial data from Verrica Pharmaceuticals Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
15 15
6% 6%
100%
- Direct Costs 1.99 1.99
10% 10%
14%
13 13
9% 9%
86%
- Selling and Administrative Expenses 44 44
38% 38%
297%
- Research and Development Expense 7.70 7.70
62% 62%
52%
-38 -38
53% 53%
-257%
- Depreciation and Amortization 1 1
5% 5%
7%
EBIT (Operating Income) EBIT -39 -39
52% 52%
-263%
Net Profit -49 -49
44% 44%
-331%

In millions USD.

Don't miss a Thing! We will send you all news about Verrica Pharmaceuticals Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Verrica Pharmaceuticals Inc Stock News

Neutral
Seeking Alpha
14 days ago
Verrica Pharmaceuticals Inc. (NASDAQ:VRCA ) Q2 2025 Earnings Conference Call August 12, 2025 4:30 PM ET Company Participants Jayson M. Rieger - President, CEO & Director John J.
Neutral
GlobeNewsWire
14 days ago
–   Company reports $12.7 million in revenue in Q2'25, consisting primarily of $4.5 million in YCANTH ® revenue, net, reflecting sequential growth of 32.5% over Q1'25 and $8.0 million in milestone revenue from Torii Pharmaceutical –
Neutral
GlobeNewsWire
20 days ago
WEST CHESTER, Pa., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or “the Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced that it will host a conference call and live webcast at 4:30 p.m. ET on Tuesday, August 12, 2025, to discuss the Company's financial results for ...
More Verrica Pharmaceuticals Inc News

Company Profile

Verrica Pharmaceuticals, Inc. operates as a clinical-stage medical dermatology company, which engages in identifying, developing, and commercializing pharmaceutical products for the treatment of skin diseases. Its lead product VP-102, is a proprietary topical therapy used in common skin indications including Molluscum contagiosum and Verruca Vulgaris. The company was founded by Matthew Davidson on July 3, 2013 and is headquartered in West Chester, PA.

Head office United States
CEO Jayson Rieger
Employees 71
Founded 2013
Website verrica.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today